SCHEMBL6880641

SCHEMBL6880641

COc1ccccc1NC=C1C(=O)Nc2ncc(-c3ccsc3)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K11 Q16584 2/20 0.47
ALDH1A1 P00352 3/20 0.43
STK10 O94804 4/20 0.42
SLK Q9H2G2 4/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HPGD P15428 1/20 0.42
PDGFRB P09619 4/20 0.40
PDGFRA P16234 4/20 0.40
RAF1 P04049 1/20 0.40
NTRK1 P04629 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CCNA1 P78396 1/20 0.40
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
JAK3 P52333 1/20 0.38
AXL P30530 1/20 0.37
FYN P06241 1/20 0.37
IDH2 P48735 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6880635 1.00 MAP3K11 (0.47) MAP3K11ALDH1A1STK10SLKNPSR1
SCHEMBL5873896 0.88 MAP3K11 (0.49) MAP3K11ALDH1A1STK10SLKNPSR1
SCHEMBL5873901 0.88 MAP3K11 (0.49) MAP3K11ALDH1A1STK10SLKNPSR1
SCHEMBL5873946 0.81 JAK3 (0.37) MAP3K11PDGFRBPDGFRAJAK3AXL
SCHEMBL5873944 0.81 JAK3 (0.37) MAP3K11PDGFRBPDGFRAJAK3AXL
SCHEMBL5873820 0.81 ALDH1A1 (0.46) MAP3K11ALDH1A1NPSR1HPGDRAF1
SCHEMBL5873815 0.81 ALDH1A1 (0.46) MAP3K11ALDH1A1NPSR1HPGDRAF1
SCHEMBL5873834 0.81 NTRK1 (0.57) MAP3K11ALDH1A1STK10SLKNPSR1
SCHEMBL5873835 0.81 NTRK1 (0.57) MAP3K11ALDH1A1STK10SLKNPSR1
SCHEMBL6884634 0.80 KDR (0.36) MAP3K11PDGFRBPDGFRAJAK3AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US claimed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US disclosed
US-6498176-B1 INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS SMITHKLINEBEECHAM CORPORATION 2002-12-24 US disclosed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US disclosed
US-6350747-B1 PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS GLAXO WELLCOME INC. 2002-02-26 US disclosed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP disclosed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX MAP3K11 97/4885ALDH1A1 4171/4885STK10 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.